Method of deriving mature hepatocytes from human embryonic stem cells
US-9512428-B2 · Dec 6, 2016 · US
US9249394B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9249394-B2 |
| Application number | US-201214007133-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 23, 2012 |
| Priority date | Mar 25, 2011 |
| Publication date | Feb 2, 2016 |
| Grant date | Feb 2, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An object of this invention is to provide a method, etc., for efficiently proliferating a pluripotent epithelial somatic stem cell. A method for producing an epithelial somatic stem cell comprising Steps (A) and (B) below: (A) expressing a gene of a protein having an activity for causing a cell in G0 phase or G1 phase to enter S phase, in a cell population including an epithelial somatic stem cell; and (B) culturing the cell obtained in Step (A) in the presence of an extracellular growth factor.
Opening claim text (preview).
The invention claimed is: 1. A method for producing an epithelial somatic stem cell, comprising: (A) expressing a gene of a protein having an activity for causing a cell in G0 phase or G1 phase to enter S phase, in a cell population comprising an epithelial somatic stem cell; and (B) culturing the cell obtained in the Step (A) in the presence of an extracellular growth factor, wherein the protein is a cyclin-dependent kinase, and wherein the cell population is a hepatic cell population. 2. The method according to claim 1 , wherein the expression is transient expression. 3. The method according to claim 1 , wherein Step (A) and Step (B) are repeated at least twice. 4. The method according to claim 1 , wherein the protein is at least one protein selected from the group consisting of cyclin-dependent kinase 4 and cyclin-dependent kinase 6. 5. The method according to claim 1 , wherein the cell population is a primary-cultured somatic cell population. 6. The method according to claim 1 , wherein the extracellular growth factor is a hepatocyte growth factor (HGF). 7. The method according to claim 1 , wherein the protein is at least one protein selected from the group consisting of cyclin-dependent kinase 1, cyclin-dependent kinase 2, cyclin-dependent kinase 3, cyclin-dependent kinase 4, cyclin-dependent kinase 6, and cyclin-dependent kinase 7.
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Genetically modified cells · CPC title
transferring phosphorus containing groups, e.g. kinases (2.7) · CPC title
Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title
containing a FLAG-tag · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.